D 086

Drug Profile

D 086

Alternative Names: D086

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chong Kun Dang
  • Class Antihyperlipidaemics; Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hyperlipidaemia; Hypertension

Most Recent Events

  • 01 May 2017 Chong Kun Dang completes a phase I trial in Hyperlipidaemia and Hypertension (In volunteers, Combination therapy, Monotherapy) in South Korea (unspecified route) (NCT03017950)
  • 01 Dec 2016 Phase-I clinical trials in Hyperlipidaemia (Combination therapy, In volunteers) in South Korea (unspecified route) (NCT03017950)
  • 01 Dec 2016 Phase-I clinical trials in Hyperlipidaemia (Monotherapy, In volunteers) in South Korea (unspecified route) (NCT03017950)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top